61 results
8-K
AEON
AEON Biopharma Inc. - Ordinary Shares
16 May 24
Departure of Directors or Certain Officers
4:27pm
certain key secondary endpoints and, in May 2024,
interim topline data from the chronic migraine cohort of the Migraine Study, which failed to achieve
8-K
EX-99
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
AEON Biopharma Reports First Quarter 2024 Financial Results
4:07pm
of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints –
– Evaluating next-steps across the Company’s late-stage … the development strategy for our pipeline.”
Recent Clinical and Corporate Highlights
Phase 2 study of ABP-450 in episodic and chronic migraine
DEFA14A
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
Additional proxy soliciting materials
9:14am
dystonia and are conducting a Phase 2 study of ABP-450 for the treatment of both chronic and episodic migraine. The topline data from the episodic … migraine cohort of the Phase 2 study was reported in October 2023 and interim topline data from the chronic migraine cohort of the Phase 2 study was reported
8-K
i6oucm2
3 May 24
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
7:01am
8-K
EX-99.1
vl1eoz
3 May 24
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
7:01am
8-K
EX-4.1
dt06bhavkv
17 Apr 24
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-99.1
reygf0 mku80up64
29 Mar 24
AEON Biopharma Announces Redemption of Public Warrants
4:16pm
8-K
EX-99.1
hu3c zcut7
29 Mar 24
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
3:46pm
8-K
EX-4.1
vlaay
28 Mar 24
Entry into a Material Definitive Agreement
4:06pm
8-K
w5g2kvt
28 Mar 24
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-99.1
ty0kvsnlg7u yqv
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm